O repositorio dixital RUNA

    • Español
    • Galego
    • English
  • Galego 
    • Español
    • Galego
    • English
  • Login
RUNABibliosaúdeXunta de galicia. Consellería de sanidadeServicio Galego de saúde
  • REPOSITORIO
  • SOBRE NÓS
    • Sobre RUNA
    • Normativa
    • Política Sergas
  • AXUDA
    • Axuda
    • FAQ
  •   RUNA Principal
  • Publicación científica
  • Ver ítem
JavaScript is disabled for your browser. Some features of this site may not work without it.

Cabergoline treatment in acromegaly: pros

Marazuela, M; Ramos-Levi, A; Sampedro-Nunez, M; Bernabeu Morón, Ignacio
Thumbnail
Estatísticas
Estatísticas
Ver Estatísticas de uso
Identificadores
Identificadores
URI: http://hdl.handle.net/20.500.11940/8195
PMID: 24532103
DOI: 10.1007/s12020-014-0206-1
ISSN: 1355-008X
Rexistro completo
Servizos
Servizos
RISMendeleyLinksolver
Visualización ou descarga de ficheiros
Visualización ou descarga de ficheiros
Texto completo disponible por cortesía de Endocrine . 2014 Jun;46(2):215-9. doi: 10.1007/s12020-014-0206-1 (214.9Kb)
Data de publicación
2014
Título da revista
ENDOCRINE
Tipo de contido
Artigo
MeSH
Acromegaly | Cabergoline | Dopamine Agonists | Drug Therapy, Combination | Ergolines | Humans | Octreotide | Treatment Outcome
Resumo
Cabergoline is an ergot-derived dopamine D2 receptor agonist which may be effective for the medical management of acromegaly. Its efficacy in reducing growth hormone and IGF-I levels, as well as its antiproliferative and pro-apoptotic effects on pituitary tumor cells, has been observed in several studies. Cabergoline may be used alone or as an add-on therapy to patients who are partially resistant to somatostatin analogs (SSA), or who do not achieve complete control with maximum doses of pegvisomant (PEG). Additionally, the convenience of its oral administration, allowing better compliance, and its lower economic cost, in comparison with SSA and PEG, favor cabergoline as an attractive option for acromegalic patients, who frequently require long-life medical treatment to achieve disease control. The few adverse events observed with prolonged DA therapy, mainly regarding cardiac valve disease, are not frequent at the doses generally used in acromegaly.

Navega

Todo RUNAColecciónsCentrosAutoresTítulosDeCSMeSHCIETipo de contidoEsta colecciónCentrosAutoresTítulosDeCSMeSHCIETipo de contido

Estatísticas

Ver Estatísticas de uso

DE INTERESE

Sobre Acceso AbertoDereitos de autor
TwitterRSS
Xunta de Galicia
© Xunta de Galicia. Información mantida e publicada na internet pola Consellería de Sanidade o Servizo Galego de Saúde
Aviso legal | RSS
Galicia